No Data
No Data
12 Health Care Stocks Moving In Tuesday's Intraday Session
KALA BIO Advances Eye Disease Therapies With New Funding
KALA BIO | 10-K: FY2024 Annual Report
KALA BIO Cash Resources of $51.2M as of Dec 31 Expected to Fund Ops Into 1Q 2026 >KALA
KALA BIO | 8-K: KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Press Release: KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update